Article · Wikipedia archive · Last revised Jul 16, 2026

5-Methylethylone

5-Methylethylone is an empathogen, stimulant and psychedelic drug of the amphetamine, phenethylamine, and cathinone chemical classes. It is structurally related to ethylone, a novel designer drug. Relatively little data exists about the pharmacological properties, metabolism, and toxicity of 5-methylethylone, though it has been sold as a designer drug.

Last revised
Jul 16, 2026
Read time
≈ 1 min
Length
252 w
Citations
4
Source
Wikipedia ↗
5-Methylethylone
source ↗
Names
Preferred IUPAC name
2-(Ethylamino)-1-(7-methyl-2H-1,3-benzodioxol-5-yl)ethan-1-one
Other names
R-MMC; 3,4-Methylenedioxy-5-methyl-N-ethyl cathinone; 5-Methyl-βk-MDEA
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C13H17NO3/c1-4-14-9(3)12(15)10-5-8(2)13-11(6-10)16-7-17-13/h5-6,9,14H,4,7H2,1-3H3
    Key: YCLKQJDSTUZDKJ-UHFFFAOYSA-N
  • CC1=CC(C(C(C)NCC)=O)=CC2=C1OCO2
Properties
C13H17NO3
Molar mass 235.283 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

5-Methylethylone (5-methyl-βk-MDEA, 5ME) is an empathogen, stimulant and psychedelic drug of the amphetamine, phenethylamine, and cathinone chemical classes.1 It is structurally related to ethylone, a novel designer drug. Relatively little data exists about the pharmacological properties, metabolism, and toxicity of 5-methylethylone, though it has been sold as a designer drug.23

United States

5-Methylethylone is unscheduled in the United States, but it is not currently approved by the Food and Drug Administration for human consumption. The state of Vermont lists it as a regulated drug.4

See also

See also

References

References

  1. "3,4-Methylenedioxy-5-methylethcathinone (hydrochloride)]". Cayman Chemical.
  2. Assi S, Gulyamova N, Kneller P, Osselton D (May 2017). "The effects and toxicity of cathinones from the users' perspectives: A qualitative study". Human Psychopharmacology. 32 (3) e2610. doi:10.1002/hup.2610. PMID 28631397.
  3. Schifano F, Napoletano F, Arillotta D, Zangani C, Gilgar L, Guirguis A, et al. (March 2020). "The clinical challenges of synthetic cathinones". British Journal of Clinical Pharmacology. 86 (3): 410–419. doi:10.1111/bcp.14132. hdl:2299/21881. PMC 7080616. PMID 31674690.
  4. Regulated Drugs Rule Archived 2014-01-23 at the Wayback Machine, Vermont Health Regulations